Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report

---

Atıf İçin Kopyala

TAÇOY G., Cengel A., ÖZKURT Z. N., TÜRKOĞLU S.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.43, sa.1, ss.78-81, 2015 (ESCI)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 43 Sayı: 1
• Basım Tarihi: 2015
• Doi Numarası: 10.5543/tkda.2015.41763
• Dergi Adı: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.78-81
• Anahtar Kelimeler: Acute lymphoblastic leukemia, dasatinib, hypertension, pulmonary
• Gazi Üniversitesi Adresli: Evet

Özet

Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary arterial pressure >= 25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is characterized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment.